Indaptus Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-0.50.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.95.
During the past 3 years, the average EBIT per Share Growth Rate was -43.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Indaptus Therapeutics's EBIT per Share or its related term are showing as below:
INDP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -43.1 Med: -43.1 Max: -43.1
Current: -43.1
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Indaptus Therapeutics was -43.10% per year. The lowest was -43.10% per year. And the median was -43.10% per year.
INDP's 3-Year EBIT Growth Rate is ranked worse than 86.8% of 1311
companies
in the Biotechnology industry
Industry Median: 3.5
vs INDP: -43.10
Indaptus Therapeutics EBIT per Share Historical Data
The historical data trend for Indaptus Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indaptus Therapeutics (NAS:INDP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Indaptus Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Indaptus Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Indaptus Therapeutics (Indaptus Therapeutics) Business Description
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in standard pre-clinical models.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INDP has been successfully added to your 